/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Acurx Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.29 -0.0091(-0.91%) ACXP at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 3.19
Highest Today 3.37
Today’s Open 3.34
Prev. Close 3.31
52 Week High 25.00
52 Week Low 3.17
Day’s Range: Low 3.19 High 3.37
52-Week Range: Low 3.17 High 25.00
1 day return -
1 Week return -17.01
1 month return -33.19
3 month return -21.07
6 month return +807.04
1 year return +317.63
3 year return -3.88
5 year return -
10 year return -

Institutional Holdings

Armistice Capital, LLC 3.40

Prospect Financial Services Llc 0.94

Geode Capital Management, LLC 0.46

Vanguard Group Inc 0.46

Vanguard Institutional Extnd Mkt Idx Tr 0.45

Morgan Stanley - Brokerage Accounts 0.34

Fidelity Extended Market Index 0.30

Renaissance Technologies Corp 0.28

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.27

Susquehanna International Group, LLP 0.22

O'Brien Greene & Co., Inc 0.19

Vanguard Capital Wealth Advisors 0.15

ACT Advisors, LLC 0.15

State Street Corp 0.14

UBS Group AG 0.12

Nbc Securities Inc 0.09

Jane Street Group LLC 0.09

Northern Trust Corp 0.09

GPS Wealth Strategies Group, LLC 0.07

Fidelity Total Market Index 0.06

Fidelity Series Total Market Index 0.06

Northern Trust Extended Eq Market Idx 0.06

NT Ext Equity Mkt Idx Fd - L 0.06

Baader Bank INC 0.05

Group One Trading, LP 0.04

Wealthcare Advisory Partners LLC 0.04

Spartan Total Market Index Pool G 0.03

NT Ext Equity Mkt Idx Fd - NL 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

Fidelity Nasdaq Composite Index 0.01

State St US Extended Mkt Indx NL Cl C 0.00

Spartan Extended Market Index Pool F 0.00

SSgA U.S. Total Market Index Strategy 0.00

Northern Trust Wilshire 5000 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

Market Status

Strong Buy: 1

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 6.90 M

PB Ratio 2.2247

PE Ratio 0.0

Enterprise Value 2.18 M

Total Assets 3.86 M

Volume 54183

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-12723689 -12.7M, FY22:-12091552 -12.1M, FY21:-12681194 -12.7M, FY20:-4600038 -4.6M, FY19:-5931253 -5.9M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-1992790 -2.0M, Q2/2025:-2246279 -2.2M, Q1/2025:-2149193 -2.1M, Q3/2024:-2821597000 -2821.6M, Q2/2024:-4121826 -4.1M

Fund house & investment objective

Company Information Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Organisation Biotechnology

Employees 4

Industry Biotechnology

CEO Mr. David P. Luci CPA, Esq., J.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow